TOLREMO closes Series A financing of CHF 9 million
TOLREMO therapeutics AG, a privately held Swiss biotech company and ETH Zurich Spin-Off, completed a series A financing round of CHF 9.0 million. The round was led by BioMedPartners with Redalpine and Altos Venture as well as TOLREMO’s existing shareholders. The capital increase will be used to advance two major drug development programs to prevent drug resistance in cancer therapies.
VISCHER advised TOLREMO; the VISCHER team includes Dr. Matthias Staehelin (Partner), Angelo Imperiale (Associate) and Luzius Zumstein (Associate), all Corporate.